New combo therapy shows promise for hard-to-treat cancers
Disease control
Completed
This study tested a new drug combination (ICT01 plus low-dose IL-2) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the combination is safe and can shrink tumors. The study also added a third drug (pembrolizumab) …
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics • Aim: Disease control
Last updated May 17, 2026 07:37 UTC